SPI Healthcare
3.592,83
PKT
+39,03
PKT
+1,10
%
Werbung
Analysen zu SPI Healthcare-Werten
Datum | Rating | Analyst | |
---|---|---|---|
03.02.05 | Roche Buy | Sarasin Research | |
03.02.05 | Roche Kaufen | LB Baden-Württemberg | |
03.02.05 | Roche In-Line | Goldman Sachs | |
03.02.05 | Novartis Übergewichten | Reuschel & Co | |
03.02.05 | Roche Buy | Sarasin Research | |
02.02.05 | Roche Halten | Helaba Trust | |
02.02.05 | Roche Buy | Sarasin Research | |
01.02.05 | Novartis Kaufen | SYZ & CO | |
01.02.05 | Roche Halten | Helaba Trust | |
31.01.05 | Lonza Reduce | Sarasin Research | |
31.01.05 | Novartis Outperform | Credit Suisse First Boston | |
31.01.05 | Roche Buy | Sarasin Research | |
01.02.05 | Roche Neutral | Credit Suisse First Boston | |
31.01.05 | Novartis Buy | Helvea | |
27.01.05 | Lonza Buy | Helvea | |
03.02.05 | Novartis Outperformer | Sparkasse KölnBonn | |
26.01.05 | Novartis Market Perform | William Blair | |
26.01.05 | Lonza Reduce | Sarasin Research | |
25.01.05 | Novartis Buy | Helvea | |
25.01.05 | Lonza Overweight | JP Morgan | |
25.01.05 | Novartis Halten | LB Baden-Württemberg | |
25.01.05 | Novartis Outperform | Goldman Sachs | |
24.01.05 | Novartis Overweight | Prudential Securities | |
24.01.05 | Novartis Neutral | Sarasin Research | |
25.01.05 | Novartis Neutral | Sarasin Research | |
24.01.05 | Straumann Outperform | Credit Suisse First Boston | |
21.01.05 | Roche Buy | Sarasin Research | |
24.01.05 | Lonza Reduce | Sarasin Research | |
24.01.05 | Novartis Kaufen | Hamburger Sparkasse | |
21.01.05 | Novartis Kaufen | Helaba Trust | |
24.01.05 | Novartis Neutral | HypoVereinsbank | |
20.01.05 | Novartis Hold | SEB | |
20.01.05 | Novartis Neutral | Sarasin Research | |
21.01.05 | Novartis Buy | Helvea | |
20.01.05 | Novartis Akkumulieren | Independent Research | |
19.01.05 | Novartis Equal-weight | Morgan Stanley | |
19.01.05 | Tecan (N) Reduce | Helvea | |
19.01.05 | Straumann Accumulate | Helvea | |
21.01.05 | Novartis Kaufen | Helaba Trust | |
18.01.05 | Novartis Buy | AG Edwards |